Last reviewed · How we verify

phylloquinone (K1)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phase 3 active Small molecule

Phylloquinone (vitamin K1) acts as a cofactor for gamma-glutamyl carboxylase, enabling the post-translational carboxylation of glutamic acid residues in vitamin K-dependent proteins involved in coagulation, bone metabolism, and vascular health.

Phylloquinone (vitamin K1) acts as a cofactor for gamma-glutamyl carboxylase, enabling the post-translational carboxylation of glutamic acid residues in vitamin K-dependent proteins involved in coagulation, bone metabolism, and vascular health. Used for Vitamin K deficiency, Coagulation disorders related to vitamin K insufficiency, Bone health and osteoporosis (investigational).

At a glance

Generic namephylloquinone (K1)
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Drug classVitamin K supplement / Cofactor
TargetGamma-glutamyl carboxylase (GGCX)
ModalitySmall molecule
Therapeutic areaNutrition / Metabolic Disorders
PhasePhase 3

Mechanism of action

Phylloquinone is the naturally occurring form of vitamin K1 found in plants. It serves as an essential cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the conversion of glutamic acid to gamma-carboxyglutamic acid in vitamin K-dependent proteins. These proteins include coagulation factors (II, VII, IX, X), osteocalcin, and matrix Gla protein, which are critical for normal hemostasis, bone mineralization, and vascular calcification regulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: